从1952年发现Bruton第一例XLA到2019年Zanubrutinib或许正式上市，这一路走来每一步都不容易，笔者写这个故事也是为了致敬为这个靶点做出贡献的科研人员。尔曹身与名俱灭，不废江河万古流。

参考资料：

[1] Sabine Ponader, et al., (2014). Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies. J Clin Oncol, 10.1200/JCO.2013.53.1046

[2] The Wild Story Behind A Promising Experimental Cancer Drug. Retrieved December 7, 2018, from https://www.forbes.com/sites/davidshaywitz/2013/04/05/the-wild-story-behind-a-promising-experimental-cancer-drug/

[3]Krysiak K, et al. Blood. 2017;129:473-483等

原标题：中国首个获FDA突破性疗法，又被称为best-in-class，百济神州Zanubrutinib及其家族的曲折诞生史